Donor selection and release criteria of cellular therapy products

摘要

Within the last two decades, an increasing number of transfusion services worldwide significantly expanded their activities on the development and production of cellular therapy (CT) products, including the provision of cellular therapeutics for their use in clinical trials [1]. Due to the increasing importance of CT for Transfusion Medicine, the Editorial Board of Vox Sanguinis decided in 2007 to establish the new section 'Cellular Therapy' as the fifth section of the journal [2]. Within the first 5 years, a yearly increasing number of manuscripts have been submitted for publication. In addition, this expanding and innovative field of Transfusion Medicine very recently leads to the foundation of a joint ISBT-AABB Working Party (WP) on Cellular Therapies with the specific purpose of developing and sharing common views on the clinical use of cellular products between the ISBT and the AABB [3].